NEWSROOM | Galderma

Galderma reaffirms its leadership in dermatology with extensive presence at EADV 2024

EADV 2024: scientific presentations supported by Galderma

Identifying unmet patient needs on World Atopic Eczema Day

Galderma launches Cetaphil Gentle Exfoliating line with Gen-Z it-girl Katie Fang

Galderma successfully issued an inaugural CHF 500 million bond

Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe

Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024

Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance

Galderma introduces high potency Cetaphil serums designed for sensitive skin

Shaping the future: Gerry Muhle on the technologies driving dermatology